Shares of Sarepta Therapeutics, Inc. (SRPT) are nosediving by nearly 45% to $17.50 in pre-market trading on Friday on a disappointing FDA Advisory Committee report concluding that “the data, overall, did not provide statistical evidence to support efficacy of eteplirsen in patients who have a confirmed mutation of the DMD gene that is amenable to […]
View the full post at: Morning Buzz: Sarepta Therapeutics (SRPT), Code Rebel Corp (CDRB), Digital Ally (DGLY), Yahoo (YHOO), Intel (INTC)